Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
D Ontaneda, E Tallantyre, T Kalincik… - The Lancet …, 2019 - thelancet.com
Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …
modifying therapies with diverse safety and efficacy profiles. The importance of early …
[HTML][HTML] Update on treatment in multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In
recent years, many disease-modifying therapies (DMT) have been approved for MS …
recent years, many disease-modifying therapies (DMT) have been approved for MS …
Emerging role of extracellular vesicles in the pathophysiology of multiple sclerosis
E Dolcetti, A Bruno, L Guadalupi, FR Rizzo… - International journal of …, 2020 - mdpi.com
Extracellular vesicles (EVs) represent a new reality for many physiological and pathological
functions as an alternative mode of intercellular communication. This is due to their capacity …
functions as an alternative mode of intercellular communication. This is due to their capacity …
Personalized use of disease-modifying therapies in multiple sclerosis
CY Lee, KH Chan - Pharmaceutics, 2024 - mdpi.com
Multiple sclerosis is an important neurological disease affecting millions of young patients
globally. It is encouraging that more than ten disease-modifying drugs became available for …
globally. It is encouraging that more than ten disease-modifying drugs became available for …
Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis
Importance As disease-modifying treatment options for multiple sclerosis increase,
comparisons of the options based on real-world evidence may guide clinical decision …
comparisons of the options based on real-world evidence may guide clinical decision …
Aggressive multiple sclerosis (2): Treatment
G Arrambide, E Iacobaeus, MP Amato… - Multiple Sclerosis …, 2020 - journals.sagepub.com
The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of
patients has what might be termed aggressive MS. These patients may have frequent …
patients has what might be termed aggressive MS. These patients may have frequent …
[HTML][HTML] Effects of natalizumab and fingolimod on clinical, cognitive, and magnetic resonance imaging measures in multiple sclerosis
Studies comparing the effects of natalizumab and fingolimod in relapsing–remitting multiple
sclerosis (RRMS) are limited. We aimed to compare natalizumab and fingolimod effects on …
sclerosis (RRMS) are limited. We aimed to compare natalizumab and fingolimod effects on …
Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing‑remitting multiple sclerosis to natalizumab treatment
P Fagone, E Mazzon, S Mammana… - Molecular …, 2019 - spandidos-publications.com
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system of
autoimmune etiopathogenesis, and is characterized by various neurological symptoms …
autoimmune etiopathogenesis, and is characterized by various neurological symptoms …
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Background Fingolimod, natalizumab, and ocrelizumab are commonly used in the second-
line treatment of relapsing-remitting multiple sclerosis (RRMS). However, these have only …
line treatment of relapsing-remitting multiple sclerosis (RRMS). However, these have only …
Disease-modifying drug uptake and health service use in the ageing MS population
Background Evidence regarding the efficacy or effectiveness of the disease-modifying drugs
(DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a …
(DMDs) in the older multiple sclerosis (MS) population is scarce. This has contributed to a …